Science?

"Let me tell you, sitting in a clinical neuroscience lab at Vanderbilt and working with people who do some of this kind of research, the technology isn't there right now. Nor do I think it ever will be, not as a limitation of the technology, but as a limitation of the assumptions one must make.
Firstly, the strength of association between a single gene and any mental illness (barring Huntington's disease) is weak at best. Secondly, the presence of a "defective" gene linked to mental illness does NOT imply the gene is being expressed. Thirdly, even if it is being expressed, there is no way to know how that one protein is interacting with other proteins, organ systems, and/or hormones."

Posted by: NAP at June 24, 2008 08:33 AM

I took this comment from Philip Dawdy FS.

I'm appalled by this post:he wrote today. I've searched on the Psynova Neurotech and could not believe what I saw:

Commercial Opportunities

Business model and commercial strategy

"Psynova Neurotech will be the vehicle for commercial exploitation of IP generated by CCNR in the field of pharmacogenomics. Value will be created by validation of key biomarkers and through the Company’s drug discovery and development programmes. In addition, the Company will exploit relevant IP created by Prof Lowe’s research into diagnostics for biomarkers identified by CCNR.
Psynova Neurotech may also act as a conduit through which pharmaceutical companies can access the PsyData database which comprises results from the unique collection of clinical samples assembled by Dr Bahn and her collaborators."

Commercial Opportunities - Marketing Opportunities

Psynova Neurotech is seeking to exploit its portfolio of proprietary biomarkers to address the following market opportunities in Neuropsychiatric disorders:

• Tests for diagnosis of patients for a pre-disposition to or with an early form of these disorders;


• Prognostic tests for assessing the likely outcome of a therapeutic intervention;


• Diagnostic tests for identifying responders to particular treatment regimes and also for stratifying patients into sub-groups for clinical studies;


• Tools to increase the effectiveness and efficiency of clinical development programmes;


• Re-profiling of current drugs for new uses with Neuropsychiatric disorders; and


• Identification of novel targets for new drug discovery programmes and the development of new classes of drugs for effective treatment of Neuropsychiatric disorders

Let's hope they will really help! Good Luck!